Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUPLE trial of durvalumab plus carboplatin and etoposide in metastatic pulmonary large-cell neuroendocrine carcinoma
2020-005942-41Phase 2Active
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Nov 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, carboplatin and etoposide in Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC) and neuroendocrine carcinoma (NEC), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Primary endpoint: Overall survival at 1 year. Started Nov 2021; status: active.
02
Drugs
durvalumabcarboplatinetoposide
03
Conditions
Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on 2020-005942-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005942-41.